EFX vs ZYME · P/E 54, rev $5.68B vs rev $76.3M
Equifax Inc (EFX) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Equifax Inc (EFX) is a consulting services company listed on US.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported EFX revenue for 2024-12-31 was $5.68B. Net income was $607.3M. Revenue was up 7.9% from 2023-12-31 to 2024-12-31. EFX currently screens at market cap $33.00B and trailing P/E 54.0.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
EFX currently screens at market cap $33.00B and trailing P/E 54.0. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the EFX and ZYME stock pages for the full models.
Not investment advice.